Abstract:Aims: The optimal strategy to identify transthyretin-type cardiac amyloidosis (ATTR-CA) in patients with aortic stenosis (AS) is still unclear. This study aimed to investigate if targeted screening for ATTR-CA in patients with severe AS and amyloid red flags is associated with higher detection rates. Methods: The study prospectively enrolled patients ≥65 years with severe AS. Patients who fulfilled ≥1 major (carpal tunnel syndrome (CTS), ruptured biceps tendon, spinal stenosis, N-terminal pro B-type natriuretic peptide ≥1000 pg/mL, cardiac troponin >99th percentile) or ≥2 minor criteria (diastolic dysfunction ≥2 grade/lateral e' 140/90 mmHg) and those with interventricular septal thickness (IVSd) ≤13 mm were excluded. Results: Overall, 264 patients were screened, of whom 85 were included in the analysis. Tracer uptake Perugini grade ≥1 was detected in nine patients (11%). An endomyocardial biopsy was additionally performed in four of nine patients, yielding a prevalence of 7% (n = 6). All patients with dual AS-ATTR were male. Syncope was more commonly reported in AS-ATTR patients (50% vs. 6%, p = 0.010), who also tended to have more severe hypertrophy (IVSd of 18 vs. 16 mm, p = 0.075). Pericardial effusion and CTS were more common in patients with dual pathology (67% vs. 8%, p < 0.001, and 83% vs. 24%, p = 0.003, respectively). Conclusion: Targeted screening for ATTR-CA in patients with AS and amyloid red flags does not yield higher detection rates than those reported previously in all comers with AS.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether screening for known amyloid red flags can improve the detection rate of transthyretin cardiac amyloidosis (ATTR - CA) in patients with severe aortic stenosis (AS). Specifically, the researchers designed a screening algorithm based on known amyloid red flags, aiming to evaluate the effectiveness of this algorithm in identifying ATTR - CA in severe AS patients with specific clinical features. ### Research Background and Objectives - **Background**: The diagnosis of transthyretin cardiac amyloidosis (ATTR - CA) in patients with severe aortic stenosis (AS) remains challenging, mainly due to the lack of specific biomarkers and the similarity between AS and ATTR - CA on echocardiography. Currently, routine bone scintigraphy screening for all AS patients is neither practical nor cost - effective in daily clinical practice. - **Objective**: This study aims to explore whether a targeted screening strategy based on known amyloid red flags can improve the detection rate of ATTR - CA in patients with severe AS. ### Research Methods - **Research Design**: This is a prospective study that included patients with severe degenerative AS who were ≥65 years old and met at least one major or two minor pre - set risk criteria. - **Major Criteria**: - Carpal tunnel syndrome (CTS) - Biceps tendon rupture - Spinal stenosis - N - terminal pro - B - type natriuretic peptide (NT - proBNP) ≥1000 pg/mL - High - sensitivity cardiac troponin I (hs - cTnI) > 99th percentile upper limit - **Minor Criteria**: - Grade II or higher diastolic dysfunction, or mitral annulus lateral wall e’ velocity < 10 cm/s measured by pulsed - wave Doppler - Atrial fibrillation - Atrioventricular conduction disorder or a history of conduction disorder requiring pacemaker implantation - **Exclusion Criteria**: Hypertension with systolic blood pressure ≥140/90 mmHg at admission, ventricular septal thickness ≤13 mm, inability to provide informed consent, or inability to perform scintigraphy for other reasons (such as frailty, dementia). ### Results - **Overall Results**: A total of 264 patients were screened, of which 85 met the analysis conditions. Bone scintigraphy detected myocardial uptake (Perugini grade ≥1) in 9 patients (11%). Four patients underwent endomyocardial biopsy, and the final diagnosis rate was 7% (n = 6). - **Clinical Features**: Compared with patients with simple AS, the characteristics of AS - ATTR patients include a higher incidence of syncope (50% vs. 6%, p = 0.010), more severe hypertrophy (IVSd 18 mm vs. 16 mm, p = 0.075), and more common pericardial effusion (67% vs. 8%, p < 0.001) and carpal tunnel syndrome (83% vs. 24%, p = 0.003). ### Conclusions - **Conclusion**: The targeted screening strategy based on known amyloid red flags did not significantly improve the detection rate of ATTR - CA in patients with severe AS, similar to the results of previous studies on all AS patients. ### Keywords - Amyloidosis - Transthyretin amyloidosis - Cardiomyopathy - Heart failure - Valvular heart disease Through the above content, this study provides important information for clinicians on how to more effectively identify ATTR - CA in patients with severe AS. Although the targeted screening strategy did not significantly improve the detection rate, the research results are helpful for further optimizing the screening method.

Screening for Occult Transthyretin Amyloidosis in Patients with Severe Aortic Stenosis and Amyloid Red Flags

Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters

Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement

Prevalence of cardiac amyloidosis among elderly patients with recent-onset atrial fibrillation. The PREVAL-ATTR study.

Histological assessment of cardiac amyloidosis in patients undergoing transcatheter aortic valve replacement

Insights into cardiac amyloidosis screening in TAVI from a Greek/Cypriot Cohort: the GRECA-TAVI registry

Amyloid Transthyretin Cardiomyopathy in Elderly Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation

Challenges in the approach to a patient with aortic stenosis and cardiac amyloidosis with ATTR mutation associated with negative scintigraphy - A case report

Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis

Assessing Screening For Transthyretin Cardiac Amyloidosis Among Patients At A Safety Net Hospital In Metro Atlanta

Efficacy of Computed Tomography-Based Evaluation of Myocardial Extracellular Volume Combined With Red Flags for Early Screening of Concealed Cardiac Amyloidosis in Patients With Atrial Fibrillation

Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study

Interpretable artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

Suspected transthyretin cardiac amyloidosis by cardiac scintigraphy in heart failure with preserved ejection fraction, left ventricular hypertrophy and red flag manifestations

Cardiac transthyretin amyloidosis in patients with conduction system disease

Echocardiographic Phenotype in Severe Aortic Stenosis With and Without Transthyretin Cardiac Amyloidosis: The AMY-TAVI Study

Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?

Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis

Cardiac amyloidosis Echo-Score for patients with severe aortic stenosis. The AMY-TAVI trial

Transthyretin amyloid cardiomyopathy in severe aortic stenosis submitted to valve replacement: a multicenter study